
Acasti Pharma ACST
Quarterly report 2025-Q3
added 11-13-2025
Acasti Pharma Cost of Revenue 2011-2025 | ACST
Cost of Revenue is a financial metric that reflects all direct costs associated with the production of goods or the provision of services that directly led to revenue during the reporting period. It is the total amount of expenses incurred by the company to deliver its products or services, including both production costs and related expenses necessary for delivery or customer support.What is included in the cost of revenue
| Cost Category | Examples |
|---|---|
| Production Costs | Materials, wages of production staff, depreciation of equipment |
| Service and Support | Customer service, user support, technical assistance |
| Delivery and Logistics | Packaging, delivery of goods to customers |
| Hosting and Infrastructure | Servers, cloud platforms (especially for IT and SaaS companies) |
| Content and Licenses | License purchases, production royalties (e.g., in streaming services) |
Importance of the Metric
- Helps to understand how costly the revenue-generating process is.
- A high cost of revenue may indicate:
Poor cost control
Low operational efficiency - A low cost of revenue combined with high revenue indicates high profitability and business competitiveness.
Annual Cost of Revenue Acasti Pharma
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | 76 K | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 76 K | 76 K | 76 K |
Quarterly Cost of Revenue Acasti Pharma
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 36 K | 36 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 36 K | 36 K | 36 K |
Cost of Revenue of other stocks in the Biotechnology industry
| Issuer | Cost of Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
AbbVie
ABBV
|
16.9 B | $ 223.01 | -0.99 % | $ 395 B | ||
|
Aclaris Therapeutics
ACRS
|
2.79 M | $ 3.38 | 3.21 % | $ 261 M | ||
|
Ampio Pharmaceuticals
AMPE
|
369 K | - | -11.43 % | $ 502 K | ||
|
Ascendis Pharma A/S
ASND
|
3.52 M | $ 212.3 | 5.5 % | $ 5 B | ||
|
Albireo Pharma
ALBO
|
1.36 M | - | -0.23 % | $ 916 M | ||
|
Ayala Pharmaceuticals
AYLA
|
602 K | - | - | $ 7.46 M | ||
|
Aptorum Group Limited
APM
|
421 K | $ 1.33 | -1.48 % | $ 7.25 M | ||
|
AstraZeneca PLC
AZN
|
12.4 B | $ 90.34 | -1.28 % | $ 96.9 B | ||
|
Amphastar Pharmaceuticals
AMPH
|
358 M | $ 25.76 | 0.19 % | $ 1.25 B | ||
|
Anika Therapeutics
ANIK
|
63.6 M | $ 9.53 | -1.19 % | $ 140 M | ||
|
BeiGene, Ltd.
BGNE
|
70.7 M | - | 0.49 % | $ 251 B | ||
|
Biogen
BIIB
|
2.31 B | $ 173.03 | -2.55 % | $ 25.2 B | ||
|
BioVie
BIVI
|
312 K | $ 1.54 | -2.53 % | $ 2.28 M | ||
|
Bellicum Pharmaceuticals
BLCM
|
436 K | - | -9.72 % | $ 5.89 M | ||
|
Berkeley Lights
BLI
|
24.8 M | - | -7.31 % | $ 87 M | ||
|
Aytu BioScience
AYTU
|
20.6 M | $ 2.33 | 2.3 % | $ 14.6 M | ||
|
Baudax Bio
BXRX
|
7.01 M | - | 0.59 % | $ 63 K | ||
|
Catalyst Biosciences
CBIO
|
4.64 M | $ 15.32 | 5.73 % | $ 1.01 B | ||
|
ChromaDex Corporation
CDXC
|
38 M | - | -0.88 % | $ 598 M | ||
|
Axon Enterprise
AXON
|
841 M | $ 586.28 | 3.15 % | $ 44.4 B | ||
|
Cerus Corporation
CERS
|
33.4 M | $ 2.14 | 13.23 % | $ 395 M | ||
|
Caladrius Biosciences
CLBS
|
31.1 M | - | -16.75 % | $ 25.8 M | ||
|
Celldex Therapeutics
CLDX
|
200 K | $ 28.33 | 0.5 % | $ 1.82 M | ||
|
BioNTech SE
BNTX
|
2.91 B | $ 95.9 | 0.17 % | $ 27.2 B | ||
|
Deciphera Pharmaceuticals
DCPH
|
3.73 M | - | - | $ 2.18 B | ||
|
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
91.7 M | $ 11.55 | 8.86 % | $ 747 M | ||
|
Dynavax Technologies Corporation
DVAX
|
49.4 M | $ 10.89 | -0.09 % | $ 1.42 B |